Double-seropositive Myasthenia Gravis Following COVID-19

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Antibodies against acetylcholine receptors (AChRs) or muscle-specific kinase (MuSK) cause MG.
• Double-seropositive MG (DSP-MG), involving both antibodies, is uncommon.

Purpose of the Study:

• To report a rare case of DSP-MG.
• To investigate the potential link between COVID-19 and DSP-MG.
• To emphasize the importance of recognizing post-viral autoimmune conditions.

Main Methods:

• Case report of a 78-year-old female patient.
• Clinical assessment of neurological symptoms (neck muscle fatigue, upper-limb weakness).
• Serological testing for anti-AChR and anti-MuSK antibodies.
• Evaluation of response to immunosuppressive therapy.

Main Results:

• The patient presented with symptoms consistent with MG following COVID-19.
• Elevated levels of both anti-AChR and anti-MuSK antibodies confirmed DSP-MG.
• The patient showed significant improvement with immunosuppressive treatment.

Conclusions:

• COVID-19 infection may trigger rare autoimmune neurological conditions like DSP-MG.
• Early diagnosis and immunosuppressive therapy are crucial for managing post-viral MG.
• This case underscores the need for vigilance regarding autoimmune sequelae after viral infections.